In allogenic SCT, patient-derived donor-specific HLA antibody (DSA)-mediated graft rejection is a rare, but serious complication. Gergis et al. 1 recently described a new therapeutic approach to reduce pre-existing DSA before allogeneic transplantation to enhance the likelihood of engraftment in 10 patients. They combined pretransplant extracorporeal antibody elimination by plasmapheresis with immunochemotherapy (rituximab, bortezomib and/or intravenous immunglobuline (i.v.IG)) and thereby achieved substantial reduction in DSA titers with sustained engraftment in nine patients.
We here report the case of a patient suffering from primary graft failure due to elevated DSA titers. Although a combination of pretransplant immunochemotherapy and third-party DLI with plasmapheresis seemed to be inefficient in reducing DSA titers alone, immunoadsorption additionally performed in the posttransplant period might have helped to achieve sufficient DSA titer reduction, thereby facilitating sustained engraftment.
A 44-year-old female with the diagnosis of AML with myelodysplastic syndrome-related changes was referred to our transplant unit in January 2014 after failing two induction cycles including one course of high-dose cytarabine. Following an extensive donor search, we identified an unrelated donor with a 10/10 match in the graft-versus-host (GvH) direction, but only a 9/10 match in the host-versus-graft direction ( Table 1 ). At that time, HLA class one and class two antibodies were identified, including a donor-specific anti-A2. As we did not type HLA-DP, we do not know whether there were additional DSA against mismatched DP. Because of refractory leukemia, the patient was treated with a sequential high-dose conditioning therapy consisting of fludarabine, amsacrine, cytarabine, i.v. busulfan and melphalan followed by transplantation of an unmanipulated peripheral blood stem cell graft containing 7.9 × 10 6 /kg CD34 + cells. Rabbit-ATG 40 mg/kg, tacrolimus and mycophenolate mofetil were used for GvHD prophylaxis. No additional action was taken to reduce the pretransplant DSA titers. Until day+20, no hematological reconstitution was observed. BM biopsy showed an acellular marrow without maturing hematopoiesis and donor chimerism of 40.5%, indicating primary graft failure. In parallel, a single antigen bead assay revealed increasing fluorescence intensities of the anti-A2 antibody (MFI 4529), suggesting this DSA as the primary cause for the graft failure.
To maximize the likelihood of engraftment of the second transplant by the elimination of the resident DSA-producing B cells, we first administered immunochemotherapy according to a modified fludarabine, cytarabine, rituximab (FCR) scheme (rituximab 3 × 375 mg/m 2 days +27 to +30, cyclophosphamide 3 × 300 mg/m 2 and fludarabine 3 × 30 mg/m 2 both days +30 to +32). Most prophylactic desensitization protocols used irradiated lymphocyte infusions (DLI) or platelet infusions from the original donor or infusion of surrogate platelets. 2 In our patient, no DLI or donor platelets were available, as this donor was prepared for the second donation. In this special situation, we took advantage of the fact that the haploidentical son carried the same mismatched A2 antigen as the donor (Table 1) . We hence isolated a total of 1.9 × 10 8 CD3 + lymphocytes/kg from the haploidentical son and infused these cells after irradiation in three fractions on days +32 and +33 (MFI 9846 before the first and MFI 7894 after last application, respectively). However, both the pharmacological intervention and third-party DLI failed to substantially decrease the DSA titers (Figure 1) . Therefore, the patient received a highdose i.v.IG (1 g/kg bodyweight) on day +33, followed by extracorporeal DSA elimination using plasmapheresis (exchange of 1, 5 plasma volumes against fresh frozen plasma) on days +34 and +35 (MFI 9538 before the first and MFI 6581 after last plasmapheresis). We observed a transient decrease in the DSA titers after each treatment, which was rapidly followed by a rebound of antibody titers the following day -a well-described phenomenon 2 (Supplementary Table S1 ). In the presence of still elevated DSA (MFI 5905), we performed the second transplant (7.8 × 10 6 CD34 + cells/kg bodyweight) on day +35 without any additional conditioning regimen apart of the FCR immunochemotherapy. This time we infused the second transplant directly into the BM. The DSA titers remained high after transplantation. We switched from plasmapheresis to immunoadsorption (IA) with regenerable protein A adsorber columns (Immunosorba, Fresenius Medical Care, Bad Homburg, Germany), for extracorporeal DSA elimination, as IA allowed an intensified daily treatment of three plasma volumes without the necessity for substitution of exchanged clotting factors with fresh frozen plasma as a potential additional source of anti-A2 antibodies. IA was performed three times on days +40 (MFI 4314) to +42, until the DSA titers were reduced to o 600 MFI. As indicated in Figure 1 , after the three sessions of IA no further rebound of DSA titers was detected during the next months. We observed sustained neutrophil and platelet engraftment on day +48 (that is, day +12 after the second transplant). BM biopsy on day +28 after the second transplant showed maturing hematopoiesis and 98.8% donor chimerism (MFI 654). After 6 months the patient still remains in remission with a full, donor-derived hematopoietic reconstitution and a low DSA titer. 
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Awareness of pretransplant DSA and the associated risk of graft failure increased during the last years, as the number of mismatched and alternative donor transplants such as haploidentical and cord blood transplants is growing. Published strategies to decrease DSA titers consist of plasmapheresis, i.v.IG, rituximab, bortezomib, donor platelet or DLI infusion so far. We used an alternative approach to circumvent DSA-associated graft rejection: (1) we administered for the first time third-party DLI of the haploidentical son, who shares the same HLA-A2 mismatch probably having caused humoral sensitization during pregnancy. (2) To prevent exposure of the transplant to the high DSA titers in serum, we injected the second transplant directly into the BM. So far, intrabone injection of blood stem cells has not been reported in the context of DSA, but is an option for cord blood transplantation to hasten hematopoietic recovery, 3 (3) We applied post-transplant-IA to achieve a sustained DSA titer reduction. IA has previously been used almost exclusively in solid organ transplantation to manage ABO incompatibility or allosensitization. In the context of alloSCT, only one patient has been reported so far in whom DSA were significantly reduced by protein A immunoadsorption. 4 In summary, our time to manage DSA-mediated graft failure was limited and we therefore sequentially applied a number of potentially effective actions. Thus, it is difficult to ascertain a definitive role of the employed intervention, and we also cannot exclude that more conventional treatment with immunochemotherapy, plasmapheresis and i.v.IG had a delayed effect on DSA titer, thereby contributing to final engraftment. However, the clinical course and the course of DSA level reduction argue in favor that IA may have contributed to decrease DSA in our patient, facilitating engraftment. In addition, intra-marrow injection of stem cells could have had a beneficial effect. Prospective studies are definitively needed to evaluate the impact of IA on reduction of the DSA titers and the associated risk of graft failure.
